Clinical Study
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection
Table 1
Baseline characteristics of 156 subjects characterized by ACE-I/ARB exposure.
| | Variable | No ACE-I/ARB (n = 114) | ACE-I/ARB (n = 42) | P value |
| | Mean age (years) ± standard deviation (SD) | 50.3 ± 8.6 | 53.4 ± 5.5 | 0.04 | | Male gender (%) | 76 (66.7) | 31 (73.8) | 0.40 | | Black race (%) | 34 (29.8) | 20 (47.6) | 0.04 | | Hispanic ethnicity (%) | 67 (58.8) | 21 (50) | 0.33 | | Mean BMI (kg/m2) ± SD | 25.6 ± 6.2 | 27.0 ± 6.8 | 0.34 | | Median HCV RNA (IU/mL) (range) | 3.66 106 (600–4.23 107) | 3.54 106 (600–3.08 107) | 0.70 | | Median log10 HCV RNA (range) | 6.56 (2.78–7.63) | 6.55 (2.78–7.49) | 0.70 | | Undetectable HIV viral load (%) | 60 (52.6) | 28 (66.7) | 0.12 | | Median HIV viral load* (copies/mL) (range) | 1.61 104 (58–8.21 105) | 421 (65–2.11 105) | 0.03 | | Median log10 HIV viral load* (range) | 4.21 (1.76–5.91) | 2.62 (1.81–5.33) | 0.03 | | Median CD4 cell count (cells/mL) (range) | 372 (11–2193) | 389 (51–1183) | 0.31 | | Alcohol Use (%) | 37 (32.5) | 9 (21.4) | 0.18 | | Prior HCV Treatment (%) | 8 (5.1) | 6 (3.8) | 0.16 | | Diagnosis of diabetes (%) | 13 (11.4) | 23 (54.8) | <0.001 | | Proteinuria (%) | 34 (32.1) | 25 (61) | <0.001 | | Mean hemoglobin A1C (g/dL) ± SD | 5.37 ± 0.66 | 6.15 ± 1.33 | 0.03 | | Significant fibrosis by clinical data (%) | 32 (28.1) | 18 (42.9) | 0.08 |
|
|
*Calculated in those with detectable HIV viral load.
|
